AHK (Tripeptide-3) 200mg (Topical)

B7-33 exibits potent anti-fibrotic effects. It is under active research and investigation as a means of reducing fibrosis in acute and chronic diseases like heart failure, lung inflammation, kidney and more. In animal studies, B7-33 has reduced fibrosis by roughly 50%, leading to prolonged survival following injury and offering the first new means of treating heart failure in 20 years. It has been shown to reduce excessive scar formation following cardiac injury. It has also shown promise in the treatment of certain vascular disorders as well as preeclampsia of pregnancy.

5-amino-1MQ is a small molecule that blocks the activity of the enzyme called nicotinamide N-methyltransferase (NNMT). By blocking NNMT, 5-amino-1MQ stimulates an increase in NAD+, a cofactor that is central to cellular metabolism, thereby increasing metabolic rate and activating a gene called sirtuin-1 (SIRT1). SIRT1 is also known as the "longevity gene" because of its role in reducing the risk of diabetes, obesity, metabolic syndrome, atherosclerosis and other forms of cardiovascular disease, kidney disease, liver disease, neurodegeneration, and cancer.